ClinicalTrials.gg

Program

oveporexton

Also written as “TAK-861”, “Oveporexton” and “TAK-861 2 mg”.

Its studies are mostly in Narcolepsy, led by Takeda.

Furthest: phase 3, since Mar 31, 20236 company-led studies, 2 open or runningNext primary completion: Dec 17, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda62 open or runningphase 3since Mar 31, 2023Jan 9, 2023Dec 17, 2026phase 3 · NCT07363720

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2023First studies: 2 phase 2 studiesFirst studyNCT05687916, NCT05687903
  2. Mar 31, 2023Phase 3 study in Narcolepsy Type 1NCT05816382 · 500 planned · United States, Australia, Finland and more
  3. Jun 18, 2024Phase 3 study in Narcolepsy Type 1NCT06470828 · 168 enrolled · United States, Canada, France and more
  4. Jul 11, 2024Phase 3 study in Narcolepsy Type 1NCT06505031 · 105 enrolled · Australia, Austria, Belgium and more
  5. Jan 7, 2026Phase 3 study in NarcolepsyNCT07363720 · 98 enrolled · United States, France, Germany and more
  6. Oct 30, 2026Primary completion moved from 2026-10-02 to 2026-12-17Date moved laterphase 3 · +2 months · NCT07363720

Ahead

  1. Dec 17, 2026Primary completion: phase 3 study in NarcolepsyNCT07363720
  2. Feb 28, 2028Primary completion: phase 3 study in Narcolepsy Type 1NCT05816382

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07363720Narcolepsy · United States, France, Germany and more3Active, not recruitingDec 17, 202698
NCT06505031Narcolepsy Type 1 · Australia, Austria, Belgium and more3CompletedJun 4, 2025105
NCT06470828Narcolepsy Type 1 · United States, Canada, France and more3CompletedJun 3, 2025168
NCT05816382Narcolepsy Type 1 · United States, Australia, Finland and more3RecruitingFeb 28, 2028500
NCT05687916Narcolepsy Type 2 · United States, Australia, Finland and more2CompletedDec 13, 202371
NCT05687903Narcolepsy Type 1 · United States, Australia, Finland and more2CompletedDec 14, 2023112

How it is read

Names in the registry

  • “TAK-861”, 4 entries
  • “Oveporexton”, 1 entry
  • “TAK-861 2 mg”, 1 entry
  • “TAK-861 2 mg and 5 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.